HMPL 662
Alternative Names: HMPL-662Latest Information Update: 25 Jul 2024
At a glance
- Originator HUTCHMED
- Class Small molecules
- Mechanism of Action RIPK1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Immunological disorders
Most Recent Events
- 31 Dec 2023 Preclinical trials in Immunological disorders in China (unspecified route) prior to December 2023 (SEC file 2023- HUTCHMED)
- 11 Jan 2021 Inmagene and HUTCHMED enters into partnership and option license agreement for development of preclinical candidates in multiple immunological disorders